Diabetes is reversed in a murine model by marginal mass syngeneic islet transplantation using a subcutaneous cell pouch device

Transplantation

Volumn 99, Issue 11, 2015, Pages 2294-2300

  Pepper, Andrew R ^a   Pawlick, Rena ^a   Gala Lopez, Boris ^a   MacGillivary, Amanda ^b   Mazzuca, Delfina M ^b   White, David J G ^c   Toleikis, Philip M ^b   James Shapiro, A M ^a,d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Sernova Corp   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; INSULIN; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; GRAFT RECIPIENT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MARGINAL MASS SYNGENEIC ISLET TRANSPLANTATION; MEDICAL DEVICE; MICROVASCULATURE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PILOT STUDY; PRIORITY JOURNAL; RENAL SUBCAPSULAR ISLET GRAFT; SUBCUTANEOUS CELL POUCH DEVICE; TISSUE TRANSPLANTATION; ANGIOGENESIS; ANIMAL; ARTIFICIAL PANCREAS; BAGG ALBINO MOUSE; BIOARTIFICIAL ORGAN; BLOOD; DEVICES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; GLUCOSE BLOOD LEVEL; ISOGRAFT; METABOLISM; PANCREAS ISLET; PATHOPHYSIOLOGY; TIME FACTOR; VASCULARIZATION;

ANIMALS; BIOARTIFICIAL ORGANS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; GLUCAGON; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE, INBRED BALB C; MICROVESSELS; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREAS, ARTIFICIAL; TIME FACTORS; TRANSPLANTATION, ISOGENEIC;

EID: 84945964061     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000864     Document Type: Article

References (39)

1. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355:1318-1330.
2. Shapiro AMJ, Ricordi C. Islet Cell Transplantation Procedure and Surgical Technique. In: Kirk SJK AD, Larsen CP, Madsen JC, Pearson TC, Webber SA, editors. Textbook of Organ Transplantation. Oxford, UK: John Wiley & Sons; 2014.
3. Harlan DM, Kenyon NS, Korsgren O, et al. Current advances and travails in islet transplantation. Diabetes. 2009;58:2175-2184.
4. Merani S, Toso C, Emamaullee J, et al. Optimal implantation site for pancreatic islet transplantation. Br J Surg. 2008;95:1449-1461.
5. Pepper AR, Gala-Lopez B, Ziff O, et al. Revascularization of transplanted pancreatic islets and role of the transplantation site. Clin Dev Immunol. 2013;2013:352315.
6. Plesner A, Verchere CB. Advances and challenges in islet transplantation: islet procurement rates and lessons learned from suboptimal islet transplantation. J Transplant. 2011;2011:979527.
7. Cheng Y, Zhang JL, Liu YF, et al. Islet transplantation for diabetic rats through the spleen. Hepatobiliary Pancreat Dis Int. 2005;4:203-206.
8. White SA, London NJ, Johnson PR, et al. The risks of total pancreatec-tomy and splenic islet autotransplantation. Cell Transplant. 2000;9:19-24.
9. Rajab A, Buss J, Diakoff E, et al. Comparison of the portal vein and kidney subcapsule as sites for primate islet autotransplantation. Cell Transplant. 2008;17:1015-1023.
10. Wahoff DC, Papalois BE, Najarian JS, et al. Autologous islet transplantation to prevent diabetes after pancreatic resection. Ann Surg. 1995;222: 562-575; discussion 575-9.
11. Christoffersson G, Henriksnäs J, Johansson L, et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes. 2010;59: 2569-2578.
12. Pattou F, Kerr-Conte J, Wild D. GLP-1-receptor scanning for imaging of human beta cells transplanted in muscle. N Engl J Med. 2010;363: 1289-1290.
13. Echeverri GJ, McGrath K, Bottino R, et al. Endoscopic gastric submuco-sal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. Am J Transplant. 2009;9:2485-2496.
14. Kakabadze Z, Gupta S, Brandhorst D, et al. Long-term engraftment and function of transplanted pancreatic islets in vascularized segments of small intestine. Transpl Int. 2011;24:175-183.
15. Kakabadze Z, Gupta S, Pileggi A, et al. Correction of diabetes mellitus by transplanting minimal mass of syngeneic islets into vascularized small intestinal segment. Am J Transplant. 2013;13:2550-2557.
16. Kakabadze Z, Shanava K, Ricordi C, et al. An isolated venous sac as a novel site for cell therapy in diabetes mellitus. Transplantation. 2012;94: 319-324.
17. Berman DM, O'Neil JJ, Coffey LC, et al. Long-term survival of nonhuman primate islets implanted inan omental pouch ona biodegradable scaffold. Am J Transplant. 2009;9:91-104.
18. Maffi P, Balzano G, Ponzoni M, et al. Autologous pancreatic islet transplantation in human bone marrow. Diabetes. 2013;62:3523-3531.
19. Tuch BE, Keogh GW, Williams LJ, et al. Safety and viability of microencap-sulated human islets transplanted into diabetic humans. Diabetes Care. 2009;32:1887-1889.
20. Sakata N, Aoki T, Yoshimatsu G, et al. Strategy for clinical setting in intramuscular and subcutaneous islet transplantation. Diabetes Metab Res Rev. 2014;30:1-10.
21. Pileggi A, Molano RD, Ricordi C, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006;81:1318-1324.
22. Toso C, McCall M, Emamaullee J, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survivalin culture. Transpl Int. 2010;23:259-265.
23. Kemp CB, Knight MJ, Scharp DW, et al. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia. 1973;9:486-491.
24. Lacy PE, Hegre OD, Gerasimidi-Vazeou A, et al. Maintenance of normoglycemia in diabetic mice by subcutaneous xenografts of encapsulated islets. Science. 1991;254:1782-1784.
25. Juang JH, Bonner-Weir S, Ogawa Y, et al. Outcome of subcutaneous islet transplantation improved by polymer device. Transplantation. 1996;61: 1557-1561.
26. Ludwig B, Rotem A, Schmid J, et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci USA. 2012;109: 5022-5027.
27. Kim JS, Lim JH, Nam HY, et al. In situ application of hydrogel-type fibrin-islet composite optimized for rapid glycemic control by subcutaneous xenogeneic porcine islet transplantation. J Control Release. 2012;162: 382-390.
28. Perez-Basterrechea M, Briones RM, Alvarez-Viejo M, et al. Plasma-fibroblast gel as scaffold for islet transplantation. Tissue Eng Part A. 2009;15:569-577.
29. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation. 2010;90: 1054-1062.
30. Kumagai-Braesch M, Jacobson S, Mori H, et al. The TheraCyte™ device protects against islet allograft rejection in immunized hosts. Cell Transplant. 2013;22:1137-1146.
31. Ludwig B, Reichel A, Steffen A, et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci USA. 2013;110: 19054-19058.
32. Sörenby AK, Kumagai-Braesch M, Sharma A, et al. Preimplantation of an immunoprotective device can lower the curative dose of islets to that of free islet transplantation: studies in a rodent model. Transplantation. 2008;86:364-366.
33. Wilson JT, Chaikof EL. Challenges and emerging technologies in the im-munoisolation of cells and tissues. Adv Drug Deliv Rev. 2008;60:124-145.
34. Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomate-rials. Semin Immunol. 2008;20:86-100.
35. Sterkers A, Hubert T, Gmyr V, et al. Islet survival and function following intramuscular autotransplantation in the minipig. Am J Transplant. 2013;13: 891-898.
36. Pileggi A, Ricordi C, Alessiani M, et al. Factors influencing Islet of Langerhans graft function and monitoring. Clin Chim Acta. 2001;310:3-16.
37. Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci. 2000;105:125-133.
38. Roep BO, Stobbe I, Duinkerken G, et al. Auto-and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes. 1999;48:484-490.
39. Jones GL, Juszczak MT, Hughes SJ, et al. Time course and quantification of pancreatic islet revascularization following intraportal transplantation. Cell Transplant. 2007;16:505-516.